Cetuximab PET Delineated Changes in Cellular Distribution of EGFR Upon Dasatinib Treatment in Triple Negative Breast Cancer

Breast Cancer Research - United Kingdom
doi 10.1186/s13058-020-01270-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Aminoflavone-Loaded EGFR-targeted Unimolecular Micelle Nanoparticles Exhibit Anti-Cancer Effects in Triple Negative Breast Cancer

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2016English

Now Is the Time to Use FDG-PET/CT to Optimize Neoadjuvant Treatment in Triple Negative Breast Cancer!

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

FZD7 in Triple Negative Breast Cancer Cells

2011English

Role of Immunotherapy in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy